Literature DB >> 17063354

Effects of topotecan treatment on nasal, buccal, and lingual mucosa in the rabbit: light and transmission electron microscopic evaluation.

Nuray Bayar Muluk1, F Figen Kaymaz, A Nur Cakar.   

Abstract

Anticancer agents may cause side effects and some of which may be dose dependant. It is important for clinicians to see the effects on tissues histopathologically. The aim of this study was to investigate the effects of topotecan (hycamtin), a topoisomerase I inhibiting anticancer agent, on nasal, buccal, and lingual mucosa of rabbits. The study was carried out in two groups each consisting of 20 rabbits. Rabbits in group I received i.v. topotecan (0.5 mg/kg once daily) for 3 days. Rabbits in group II received i.v. topotecan (0.25 mg/kg once daily) for 3 days. In group I and II, biopsies from the nasal, buccal, and lingual mucosa were taken on the fourth (1 day after the 3-day topotecan treatment) and 15th day (12 days after the 3-day topotecan treatment). Light and transmission electron microscopic (TEM) observations have shown that nasal mucosa was not affected by topotecan administration. Topotecan treatment resulted in the formation of some ulcerative lesions in the lingual mucosa especially on the lower surface of the tongue. On the dorsal surface, the epithelium showed highly edematous and degenerating cells and separations in the stratum granulosum. In the buccal mucosa, effects were similar. In lingual and buccal mucosa, healing was observed on the 15th day. The oral (lingual and buccal) mucosal side effects of topotecan were observed as reversible and not dose dependent. It was concluded that these side effects are not severe, and topotecan may be used safely in cancer treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17063354     DOI: 10.1007/s00405-006-0181-0

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  24 in total

1.  Salivary and plasma pharmacokinetics of topotecan in patients with metastatic epithelial ovarian cancer.

Authors:  M Boucaud; F Pinguet; S Poujol; G Romieu; D Cupissol; C Astre; S Culine; F Bressolle
Journal:  Eur J Cancer       Date:  2001-12       Impact factor: 9.162

2.  [Pharmacokinetics of SK & F 104864 in experimental animals. I. Plasma level].

Authors:  H Fujita; M Okamoto; A Takao; H Abe; R Ishii; K Takeda
Journal:  Gan To Kagaku Ryoho       Date:  1995-10

3.  Topotecan: An Oncologist's View.

Authors: 
Journal:  Oncologist       Date:  1998

4.  The accumulation of topotecan in 9L glioma and in brain parenchyma with and without dexamethasone administration.

Authors:  C S Straathof; M J van den Bent; W J Loos; C J Vecht; J H Schellens
Journal:  J Neurooncol       Date:  1999-04       Impact factor: 4.130

5.  A phase II study of topotecan in patients with recurrent head and neck cancer. Identification of an active new agent.

Authors:  F Robert; S J Soong; R H Wheeler
Journal:  Am J Clin Oncol       Date:  1997-06       Impact factor: 2.339

Review 6.  Topoisomerase I inhibitors in the treatment of head and neck cancer.

Authors:  B A Murphy; A Cmelak; B Burkey; J Netterville; Y Shyr; S Douglas; W Smith
Journal:  Oncology (Williston Park)       Date:  2001-07       Impact factor: 2.990

Review 7.  [Poisons of DNA topoisomerases I and II].

Authors:  J Y Charcosset; S Soues; F Laval
Journal:  Bull Cancer       Date:  1993-11       Impact factor: 1.276

Review 8.  Topotecan: a new topoisomerase I inhibiting antineoplastic agent.

Authors:  R J Cersosimo
Journal:  Ann Pharmacother       Date:  1998-12       Impact factor: 3.154

9.  Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia.

Authors:  H M Kantarjian; M Beran; A Ellis; L Zwelling; S O'Brien; L Cazenave; C Koller; M B Rios; W Plunkett; M J Keating
Journal:  Blood       Date:  1993-03-01       Impact factor: 22.113

10.  Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor.

Authors:  E K Rowinsky; L B Grochow; C B Hendricks; D S Ettinger; A A Forastiere; L A Hurowitz; W P McGuire; S E Sartorius; B G Lubejko; S H Kaufmann
Journal:  J Clin Oncol       Date:  1992-04       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.